At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 41 enrolled
Drug / intervention
Olaratumab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label, Multicenter, Phase 1a/1b Study of Olaratumab (LY3012207) Plus Pembrolizumab (MK3475) in Patients With Unresectable Locally Advanced or Metastatic Soft Tissue Sarcoma (STS) Who Have Failed Standard Treatments
In Brief
A Phase 1 clinical trial evaluating Olaratumab and Pembrolizumab (KEYTRUDA®) for Soft Tissue Sarcoma. Completed, enrolled 41 participants across 6 sites in 4 countries.
Detailed Summary
The purpose of this study is to evaluate the safety of olaratumab plus pembrolizumab in participants with previously treated advanced or metastatic soft tissue sarcoma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSoft Tissue Sarcoma
CountriesBelgium, Denmark, France, United States
CollaboratorsMerck Sharp & Dohme LLC
Timeline
Phase 1CompletedFinished
201820192020202120222023202420252026
First PostedApr 2017
Enrollment StartJul 2017
Primary CompletionMay 2021
Study CompletionFeb 2023
TodayJul 2026
First PostedApr 24, 2017
Enrollment StartJul 3, 2017
Primary CompletionMay 6, 2021
Study CompletionFeb 21, 2023
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 9.2 years ago
Interventions
Olaratumabdrug
Administered IV
Pembrolizumab (KEYTRUDA®)drug
Administered IV